Private Capital Group LLC lifted its position in Sanofi SA (NYSE:SNY) by 271.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,577 shares of the company’s stock after acquiring an additional 1,883 shares during the period. Private Capital Group LLC’s holdings in Sanofi were worth $103,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently modified their holdings of the company. STA Wealth Management LLC acquired a new stake in shares of Sanofi in the fourth quarter worth approximately $58,996,000. Whittier Trust Co. boosted its stake in shares of Sanofi by 290.0% in the first quarter. Whittier Trust Co. now owns 3,362 shares of the company’s stock worth $135,000 after acquiring an additional 2,500 shares during the last quarter. We Are One Seven LLC acquired a new stake in shares of Sanofi in the fourth quarter worth approximately $160,000. Bray Capital Advisors acquired a new stake in shares of Sanofi in the first quarter worth approximately $155,000. Finally, IHT Wealth Management LLC boosted its stake in shares of Sanofi by 246.6% in the first quarter. IHT Wealth Management LLC now owns 4,239 shares of the company’s stock worth $167,000 after acquiring an additional 3,016 shares during the last quarter. 8.46% of the stock is currently owned by hedge funds and other institutional investors.
In other Sanofi news, major shareholder Sanofi sold 121,601 shares of the business’s stock in a transaction on Friday, June 8th. The stock was sold at an average price of $309.31, for a total transaction of $37,612,405.31. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 1.00% of the company’s stock.
NYSE SNY opened at $40.00 on Monday. The firm has a market cap of $97.89 billion, a price-to-earnings ratio of 12.78, a P/E/G ratio of 1.85 and a beta of 0.84. The company has a current ratio of 1.70, a quick ratio of 1.26 and a debt-to-equity ratio of 0.25. Sanofi SA has a fifty-two week low of $37.43 and a fifty-two week high of $50.65.
Sanofi (NYSE:SNY) last released its quarterly earnings data on Friday, April 27th. The company reported $0.79 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.05. The company had revenue of $7.90 billion for the quarter, compared to analyst estimates of $7.88 billion. Sanofi had a return on equity of 24.45% and a net margin of 10.93%. The firm’s revenue for the quarter was down 8.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.42 earnings per share. equities analysts anticipate that Sanofi SA will post 3.21 EPS for the current year.
A number of analysts have recently issued reports on the company. Liberum Capital raised Sanofi from a “hold” rating to a “buy” rating in a research note on Friday, March 23rd. Deutsche Bank reaffirmed a “buy” rating on shares of Sanofi in a research note on Monday, March 12th. Zacks Investment Research lowered Sanofi from a “hold” rating to a “sell” rating in a research note on Tuesday, April 17th. Finally, ValuEngine lowered Sanofi from a “hold” rating to a “sell” rating in a research note on Wednesday, May 2nd. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $49.33.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulator and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.